SLC5A2 and diabetes mellitus: Meanwhile, other KEGG analysis results that explore the same and different signaling pathways between four SGLT2 inhibitors showed that the four key pathways mentioned above were contained in 125 pathways overlapping in two or more SGLT2 inhibitors, which also indicated that the four pathways might play a key part in the treatment of DM with HF by SGLT2 inhibitors.